At a glance
CNCR charges 0.79% a year, above the 0.47% average of the 6 funds most like it (the most expensive of 7). It has $8.9M in assets, the 7th largest of that group. Over the past year it returned +0.0% with distributions reinvested (S&P 500: +11.5%), the weakest of those 7 funds; over three years it returned −0.8% a year. At its worst it fell 30.2% in the 2020 crash (S&P 500: 33.7%) and 46.5% in the 2022 bear market (S&P 500: 24.5%). Its ten largest positions make up 26.9% of the fund, out of 75 in all.
The short version
Range Cancer Therapeutics ETF (CNCR) is an index fund tracking the Range Oncology Therapeutics Index, roughly 85 US-listed drug and biotech companies focused on cancer treatment. It offers a targeted stake in cancer drugs and gives each stock an equal slice at twice-yearly rebalances, so small developers count as much as Bristol-Myers Squibb. Its 0.79% annual fee is the highest among similar funds, and it fell 75.8% from February 2021 to April 2025.
Price history
The interactive chart needs JavaScript.
CNCR 0.0% over the year to Oct 27, 2026, total return with distributions reinvested.
How it has behaved
| YTD | 1 yr | 3 yr | 5 yr | 10 yr | Since start | |
|---|---|---|---|---|---|---|
| CNCR price data to Oct 27, 2026 | 0.0% | 0.0% | -0.8% | -19.4% | -7.4% | -8.0% |
- Over the year to Oct 27, 2026, CNCR returned 0.0%, 7th of 7 among similar funds.
- Its 5-year annualized return was -19.4% and its 10-year -7.4%.
- In the 2020 COVID crash it fell 30.2% and regained its old high 1.1 months after the low.
- Its worst full calendar year was 2022 (-42.3%); its best was 2020 (+36.5%).
- The deepest fall in its price history was 75.8% (Feb 8, 2021 to Apr 8, 2025), not yet recovered.
Show as a table
| Year | Price data |
|---|---|
| 2025 | -26.7% |
| 2024 | -8.6% |
| 2023 | -1.9% |
| 2022 | -42.3% |
| 2021 | -19.1% |
| 2020 | +36.5% |
| 2019 | +24.2% |
| 2018 | -20.6% |
| 2017 | +13.6% |
| 2016 | -25.6% |
| 2008 financial crisis stocks fell Oct 9, 2007 – Mar 9, 2009 | Before this security existed |
|---|---|
| 2020 COVID crash stocks fell Feb 19, 2020 – Mar 23, 2020 | Lost 22.1% over that stretch · deepest drop along the way 30.2%, back to its old high 1.1 months after the low |
| 2022 bear market stocks fell Jan 3, 2022 – Oct 12, 2022 | Lost 39.5% over that stretch · deepest drop along the way 46.5%, not recovered by the end of the data |
Dividends and income
Show as a table
| Year | Per share | Change |
|---|---|---|
| 2021 | $1.8500 | +537.9% |
| 2020 | $0.2900 | -17.1% |
| 2017 | $0.3500 |
What's inside
As of Feb 28, 2025, the fund held 75 securities; the ten largest made up 26.85% of assets.
| Holding | Weight | |
|---|---|---|
| Recursion Pharmaceuticals Inc | 4.01% | |
| Precigen Inc | 3.05% | |
| Compass Therapeutics Inc | 2.99% | |
| Genelux Corp | 2.90% | |
| SpringWorks Therapeutics Inc | 2.86% | |
| Exelixis Inc | 2.48% | |
| Ginkgo Bioworks Holdings Inc | 2.33% | |
| Replimune Group Inc | 2.14% | |
| Bristol-Myers Squibb Co | 2.10% | |
| Schrodinger Inc/United States | 1.98% | |
| Blueprint Medicines Corp | 1.97% | |
| Zymeworks Inc | 1.89% | |
| Vor BioPharma Inc | 1.88% | |
| HUTCHMED China Ltd | 1.76% | |
| Innate Pharma SA | 1.73% |
By country
United States 86.76%United Kingdom 3.11%Germany 2.22%Hong Kong 1.76%France 1.73%By asset type
Stocks 99.35%What changed recently
- Over the three months to Feb 28, 2025, investors withdrew a net $610K (creations minus redemptions, per the N-PORT report).
- Monthly total returns reported for that quarter: -14.01%, +0.52%, -7.53%.
How it works
CNCR is an index fund: it aims to match the Range Oncology Therapeutics Index, before fees, rather than pick stocks. Range Fund Holdings created the index in 2023. It holds roughly 85 US-listed drug and biotech stocks with market values above $250 million, including American Depositary Receipts (US-traded shares of foreign companies). A company qualifies if cancer products bring in at least 50% of its sales, or if cancer drugs in testing make up at least 50% of its pipeline value. China-based companies are excluded.
Each stock gets an equal weight when the index is rebuilt and rebalanced on the third Tuesday of June and December. Weights then drift as prices move. As of February 28, 2025, the fund held 75 stocks. The largest were Recursion Pharmaceuticals (4.0%), Precigen (3.1%) and Compass Therapeutics (3.0%), and the top 10 made up about 27% of assets.
The adviser, Exchange Traded Concepts, generally holds every index stock. When that is impractical or costly, it may hold a smaller sample with similar traits, and it can keep up to 20% of assets outside the index to help track it. Because every index stock is a drug or biotech company, the fund is concentrated in one corner of health care. It held no derivatives as of February 28, 2025.
What it really costs
- CNCR charges 0.79% a year, versus an average of 0.47% for the similar funds below (7th of 7, cheapest first).
- Using the prospectus's standard example, $10,000 invested would cost about $81 in the first year and $978 over 10 years (assuming a 5% annual return).
| Cost of $10,000 (SEC example) | 1 yr | 3 yrs | 5 yrs | 10 yrs |
|---|---|---|---|---|
| CNCR | $81 | $252 | $439 | $978 |
In a retirement portfolio
It is a tiny, single-theme fund of cancer-drug stocks with deep, unrecovered losses and no income, so any place for it would be as a small add-on.
CNCR could add targeted exposure to cancer-drug companies, which make up only a small slice of broad stock funds. In the 2020 COVID crash it fell 30.2% from March 4 to March 16, 2020, then regained its peak by April 17. In the 2022 stock slump it dropped 46.5% from January 3 to June 13, 2022, and 2022 was its worst calendar year, down 42.3%. Its deepest fall, 75.8% from February 8, 2021 to April 8, 2025, was still unrecovered as of October 27, 2026. It launched after the 2008 crisis.
Someone who needs cash in a bad year could end up cashing in shares at a steep loss. It paid no income in the year to October 27, 2026, and its 0.79% fee exceeds the 0.47% average of similar funds. Past results don't predict the future, and a plan needs to look at the whole portfolio, not one fund.
Who it may suit — and who should look elsewhere
May suit
- Investors wanting a targeted stake in cancer-drug developers such as Recursion Pharmaceuticals, Precigen and Exelixis, sized as a small part of a portfolio.
- Those who prefer equal weighting, where each holding starts with the same slice at June and December rebalances rather than letting the largest companies dominate.
- Investors with a long horizon who can tolerate deep losses, like the 46.5% drop from January to June 2022, without needing to cash out.
Look elsewhere if
- Cost-conscious investors: its 0.79% fee tops all six similar funds compared, including SPDR S&P Biotech ETF (XBI) at 0.35%.
- Anyone needing portfolio income: CNCR paid no distributions in the year to October 27, 2026, and its holdings are chosen for cancer focus, not dividends.
- Investors wary of a small fund closing: it held just $8.9 million as of February 28, 2025, the smallest in its comparison group.
Close alternatives
Matched by closest holdings overlap from the latest N-PORT reports (no similar fund shares 20% or more of its holdings).
| Fund | Overlap | Cost | Net assets | 1 yr | 3 yr |
|---|---|---|---|---|---|
| CNCR this fund | — | 0.79% | $8.9M | 0.0% | -0.8% |
| CANC Tema Oncology ETF | 27% | 0.75% | $211.1M | +35.4% | +26.7% |
| XBI SPDR S&P Biotech ETF | 17% | 0.35% | $10.73B | +39.3% | +34.4% |
| IBB iShares Biotechnology ETF | 11% | 0.45% | $9.09B | +35.3% | +23.9% |
| FBT First Trust NYSE Arca Biotechnology Index F… | 7% | 0.56% | $2.81B | +43.6% | +27.7% |
| FXH First Trust Health Care AlphaDEX Fund | 6% | 0.6% | $1.05B | +19.7% | +15.1% |
| VHT Vanguard Health Care ETF | 6% | 0.09% | $22.04B | +28.9% | +16.9% |
Questions investors ask
What stocks are in CNCR?
CNCR holds cancer-focused drug and biotech stocks: 75 of them as of February 28, 2025. The largest were Recursion Pharmaceuticals (4.0%), Precigen (3.1%), Compass Therapeutics (3.0%), Genelux (2.9%) and SpringWorks Therapeutics (2.9%), while Bristol-Myers Squibb was 2.1%. Because the index gives each stock an equal weight at each rebalance, the top 10 made up only about 27% of assets. About 87% was in US companies, with smaller stakes in companies based in the United Kingdom, Germany and France.
How has CNCR performed over the long term?
It has lost money over longer stretches. As of October 27, 2026, it lost an average of 19.4% a year over five years, about 66% in total, and 7.4% a year over 10 years. It fell in every calendar year from 2021 through 2025, including a 42.3% drop in 2022. Its strongest quarter was a 36.76% gain in the quarter ended June 30, 2020. The fund launched in October 2015, but its current index dates to 2023, so most of this record predates that index.
Does CNCR pay a dividend?
No. CNCR paid no distributions in the year to October 27, 2026, so its trailing yield (the income paid over the past year as a share of the price) was 0%. The fund picks stocks for their focus on cancer drugs, not for income, and drug developers often pour their cash into research rather than paying dividends. Retirees who rely on portfolio income would need to get it from other holdings.
What's the difference between CNCR and CANC?
Both focus on cancer-drug companies, but CANC is far larger and slightly cheaper. Tema Oncology ETF (CANC) charges 0.75% a year versus CNCR's 0.79%. CANC held about $211 million as of August 31, 2026, against CNCR's $8.9 million as of February 28, 2025. CANC is CNCR's closest match by holdings, yet the two share only a minority of their stocks. CNCR follows an equal-weighted index of roughly 85 stocks, rebalanced each June and December, so their returns can differ.
What is CNCR's expense ratio?
CNCR's expense ratio, the yearly fee taken out of fund assets, is 0.79%, all of it management fee, according to its prospectus filed December 20, 2024. In the SEC's standard example, $10,000 earning 5% a year would cost $81 after one year, $252 after three, $439 after five and $978 after 10 years, assuming the shares are cashed in at the end. That is more than all six similar funds compared, which average 0.47%. SPDR S&P Biotech ETF (XBI) charges 0.35%.